Expecto Health Science Partners with VertisPro to Deploy AI-Driven Patient Recruitment in Asia-Pacific Clinical Trials
核心洞察
Expecto Health Science (搜索), an Asia-Pacific Contract Research Organisation, has announced a strategic collaboration with VertisPro (搜索) to integrate AI-driven patient acquisition solutions into clinical trials.
The partnership aims to address patient recruitment challenges in rare disease (搜索) and oncology (搜索) trials by improving patient identification accuracy and shortening recruitment timelines.
VertisPro (搜索)'s artificial intelligence platform will be integrated into Expecto's service offerings to help sponsors achieve better trial enrollment success rates across the region.
Expecto Health Science (搜索), an emerging Asia-Pacific Contract Research Organisation (CRO), has announced a strategic collaboration with VertisPro (搜索) to integrate artificial intelligence-driven patient recruitment solutions into clinical trials across the region. The partnership addresses one of the most significant challenges facing clinical trial sponsors in Asia-Pacific: patient recruitment, particularly in rare disease (搜索) and oncology (搜索) studies.
Strategic Integration of AI Technology
Through this collaboration, Expecto will integrate VertisPro (搜索)'s advanced AI recruitment solution into its comprehensive service offering. The integration is designed to enable sponsors to identify eligible patients with greater accuracy, shorten recruitment timelines, and improve overall trial enrollment success rates.
Expecto Health Science (搜索) brings established expertise in regulatory strategy, clinical trial planning and management across multiple therapeutic areas, including oncology (搜索), infectious diseases (搜索), medical devices, and cosmetic research. The company's operational capabilities will now be enhanced by VertisPro (搜索)'s technology platform, which uses artificial intelligence to streamline patient identification and engagement processes.
Leadership Perspectives on the Partnership
"The best collaborations happen when both parties bring complementary strengths," said Dr. Pramod Kashid, CEO of Expecto Health Science (搜索). "Our operational expertise now pairs with VertisPro (搜索)'s proven recruitment technology, ensuring sponsors have the tools and support needed to meet enrollment targets efficiently."
VertisPro (搜索) CEO Harshad Puppalwar emphasized the value proposition of combining clinical operations knowledge with advanced technology. "This partnership combines Expecto's deep clinical operations knowledge with our technology to deliver tangible value to sponsors," he stated. "Together, we aim to set a new benchmark for recruitment efficiency in clinical trials."
Addressing Regional Recruitment Challenges
The collaboration specifically targets the persistent challenge of patient recruitment in Asia-Pacific clinical trials, where rare disease (搜索) and oncology (搜索) studies face particular difficulties in achieving enrollment targets. VertisPro (搜索)'s platform provides sponsors with measurable improvements in recruitment performance through its AI-driven approach to patient identification and engagement.
The partnership reflects both companies' shared mission to advance clinical development, improve trial efficiency, and accelerate patient access to innovative therapies across the Asia-Pacific region.